Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck
Portfolio Pulse from
Protagonist Therapeutics is anticipating significant developments in 2025, including results from the phase 3 VERIFY study for rusfertide in treating polycythemia vera and positive outcomes from ICONIC studies using JNJ-2113 for plaque psoriasis. The global market for polycythemia vera is projected to grow significantly by 2032.
January 13, 2025 | 11:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Protagonist Therapeutics is set for potential growth with upcoming 2025 catalysts, including VERIFY study results for rusfertide and ICONIC study outcomes for JNJ-2113.
The upcoming results from the VERIFY study and ICONIC studies are significant for PTGX as they could lead to new treatment approvals and market expansion. The anticipated growth in the polycythemia vera market further supports potential revenue increases.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100